|Bid||0.105 x 0|
|Ask||0.110 x 0|
|Day's Range||0.105 - 0.125|
|52 Week Range||0.055 - 1.130|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to announce that it has entered into a definitive agreement (the “Agreement”) with Emerald Health Therapeutics, Inc. (“Emerald”) to dispose of (the “Disposition”) its 35% interest in Northern Vine Canada Inc. (“Northern Vine”) in exchange for $2 million in cash and $4 million in freely tradeable common shares of Emerald. The Agreement also provides that, upon Northern Vine and/or Emerald earning gross revenues of $10 million from the sale of products or services to customers introduced by Abattis, Emerald will issue Abattis a further $4 million in common shares of Emerald.
Emerald Health Therapeutics, Inc. (EMH.V) (EMHTF) (Emerald) has signed a definitive agreement (“Agreement”) to acquire the remaining shares of Northern Vine Canada Inc. (Northern Vine), owned by Abattis Bioceuticals Corp. (Abattis) (CSE:ATT) (ATTBF), for $2 million in cash and $4 million in shares of Emerald stock. Northern Vine is a Licensed Dealer (LD) under the provisions of the Canadian Controlled Drugs and Substances Act. “Product innovation is a primary pillar of Emerald’s global business strategy.
Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to provide the following corporate updates. Abattis has completed a non-brokered private placement for gross proceeds of $2.25 million (the “Proceeds”) through the issuance of 13,235,294 common shares of the Company priced at $0.17 per share. The Company anticipates that the Proceeds will be used to organically grow its existing downstream service division and for general working capital purposes.
Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce that it has entered into a definitive investment agreement dated June 27, 2018 (the “Agreement”) with XLABS Therapeutics (ONT) Inc. (“XLABS”) to launch a new Cannabis laboratory in Belleville, Ontario (the “Laboratory”). The Laboratory will be designed to service Ontario’s growing cannabis sector, which currently numbers 59 licensed producers (“LPs”). “This is another very significant milestone for Abattis,” stated Rob Abenante, President and CEO of Abattis.
OTC:ATTBF) ("Abattis") and BLOCKSTRAIN TECHNOLOGY CORP. ("BLOCKStrain") (TSXV: DNAX.V) are pleased to announce that they have signed a letter of intent (the "LOI") to integrate BLOCKStrain's proprietary technology into Abattis's product and services ecosystem. Through their collaboration, the parties hope to enable Abattis clients to instantly arrange for sales, shipping, testing and analysis of Abattis products and give clients comprehensive visibility over such products over their entire lifecycles. Abattis and BLOCKStrain also intend to explore development and integration opportunities to expand on Abattis's current life sciences and biotechnology services offerings.
VANCOUVER, British Columbia, May 24, 2018-- Abattis Bioceuticals Corp. and its wholly-owned subsidiary, Vergence Naturals Ltd., have launched their“ Live. ”marketing campaign to build awareness for their ...
Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to announce the addition of three new vaporizers to its product line. Since the Company’s acquisition of Green Tree Therapeutics (“Green Tree”) earlier this year, Abattis has been working to expand its retail presence and product line and is now ready to release its first three vaporizers, the VB-1, VB-2 and the KB-1.
Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to announce it has entered into a non-binding letter of intent (the "LOI") with Cannamedix Inc. (“Cannamedix”) to provide Cannamedix with, among other things, pesticide-free cannabinoid-containing oils, research and development, analytical and regulatory services and access to Abattis’s distribution and marketing channels to support the development and commercialization of new CBD-infused nutraceuticals and natural health products. Cannamedix is a Calgary-based healthcare provider focused on the use of traditional and alternative therapies to address health conditions, from pain management to integrative cancer care. Pursuant to the LOI, Abattis and Cannamedix have agreed to negotiate in good faith the terms of a definitive agreement respecting the terms of their partnership.
CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Vancouver, BC based Abattis Bioceuticals Corp.'s (ATT.CN) (ATT.CN) (ATT.CN) (ATTBF) intense focus on downstream cannabis products. For those thinking about longer-term implications, the writing is on the wall: cannabis flower will follow, at some point in the not too distant future, every other commodity and the prices will go down as supply meets and exceeds demand. Merchandise derived from cannabis, like oil extracts, edibles, nutraceuticals, and personal care products, are increasingly popular with consumers who are interested in the benefits of cannabis but not interested in smoking the flower.
Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to announce the appointments of Kent McParland, Brazos Minshew, Shawn Balaghi and Jim Carter to the Company’s leadership team and Wolfgang Richter to its Board of Directors.
Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to announce the engagement (the “Engagement”) of Ocean Pacific Contractors Ltd. (“Ocean Pacific”) for construction of a purpose-built 26,000 square foot cannabis production and extraction facility (the “Facility”) on Gabriola Island, British Columbia. The Engagement follows completion of the Company’s recent acquisition of the remaining 10% interest in Gabriola Green Farms Inc. (“Gabriola”) from CannaNUMUS Blockchain Inc., as a result of which Gabriola is now a wholly-owned subsidiary of the Company.
Vancouver, British Columbia--(Newsfile Corp. - April 30, 2018) - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE: ATT / OTC: ATTBF) is pleased to announce, further to its news release dated April 18, 2018, that it has completed its acquisition of the remaining 10% ownership interest (the "Interest") in its subsidiary, Gabriola Green Farms Inc. ("Gabriola"). Abattis acquired the Interest from CannaNUMUS Blockchain Inc. for $2.5 million. Gabriola is now a wholly-owned subsidiary of the ...
Vancouver, British Columbia--(Newsfile Corp. - April 18, 2018) - Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) (the "Company" or "Abattis") is pleased to announce that it has entered into a share purchase agreement to acquire (the "Acquisition") the remaining 10% ownership interest in its subsidiary, Gabriola Green Farms Inc. ("Gabriola")."We are very happy to now own a 100% interest in Gabriola and integrate it as a wholly-owned subsidiary of Abattis. We believe that Gabriola's anticipated LP ...
Vancouver, British Columbia--(Newsfile Corp. - April 13, 2018) - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE: ATT) (OTCQB: ATTBF) is pleased to announce the addition of Cameron Paddock to the Board of Directors. Mr. Paddock will fill the vacancy left by the resignation of Dr. Will Panenka who is leaving the Company to concentrate on other ventures."We are very excited have Mr. Paddock join our Board. On behalf of the Company, I would like ...
Vancouver, British Columbia--(Newsfile Corp. - March 26, 2018) - Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) (the "Company" or "Abattis") announces a correction to its news release dated March 13, 2018 (the "Release"). In the Release, Canadian Artesian Ice Ltd. ("Canadian Artesian") was described as being the bottlers of Clearly Canadian products. However, the Company has since been advised that Canadian Artesian are not the bottlers of Clearly Canadian products. About Abattis Bioceuticals Corp. Abattis ...
TORONTO, March 19, 2018 /CNW/ - Horizons ETFs Management (Canada) Inc. ("Horizons ETFs") completed the quarterly rebalance of the constituent holdings of the Horizons Marijuana Life Sciences Index ETF ("HMMJ") on March 16, 2018.
Abattis Signs LOI with Canadian Artesian Ice, Bottlers of Clearly Canadian products, to Manufacture CBD-infused Mineral Water